Current and future G protein-coupled receptor signaling targets for heart failure therapy

References

• Kaye DM Krum H Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Disc 2007 6 2 127 139
   Web of Science ®Google Scholar
• Swedberg K Cleland J Dargie H Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 2005 26 11 1115 1140 15901669
   PubMed Web of Science ®Google Scholar
• Abhayaratna W Smith WT Becker NG Marwick TH Jeffery IM McGill DA Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study Med J Aust 2006 184 4 151 154 16489896
   PubMed Web of Science ®Google Scholar
• Levy D Kenchaiah S Larson MG Long-term trends in the incidence of and survival with heart failure N Engl J Med 2002 347 18 1397 1402 12409541
   PubMed Web of Science ®Google Scholar
• Roger VL Weston SA Redfield MM Trends in heart failure incidence and survival in a community-based population JAMA 2004 292 3 344 350 15265849
   PubMed Web of Science ®Google Scholar
• Mosterd A Hoes AW de Bruyne MC Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam Study Eur Heart J 1999 20 6 447 455 10213348
   PubMed Web of Science ®Google Scholar
• Cleland JG Khand A Clark A The heart failure epidemic: exactly how big is it? Eur Heart J 2001 22 8 623 626 11286518
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Bathgate A Arrestins in the cardiovascular system Prog Mol Biol Transl Sci 2013 118 297 334 23764059
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Rengo G Koch WJ Adrenergic nervous system in heart failure: pathophysiology and therapy Circ Res 2013 113 739 753 23989716
   PubMed Web of Science ®Google Scholar
• Lin HH G-protein-coupled receptors and their (Bio) chemical significance win 2012 Nobel Prize in chemistry Biomed J 2013 36 3 118 124 23806881
   PubMedGoogle Scholar
• Lymperopoulos A Rengo G Koch WJ GRK2 inhibition in heart failure: something old, something new Curr Pharm Des 2012 18 2 186 191 22229578
   PubMed Web of Science ®Google Scholar
• Skeberdis VA Gendviliene V Zablockaite D Beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current J Clin Invest 2008 118 9 3219 3227 18704193
   PubMed Web of Science ®Google Scholar
• Gauthier C Leblais V Kobzik L The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle J Clin Invest 1998 102 7 1377 1384 9769330
   PubMed Web of Science ®Google Scholar
• Rozec B Erfanian M Laurent K Trochu JN Gauthier C Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart J Am Coll Cardiol 2009 53 17 1532 1538 19389564
   PubMed Web of Science ®Google Scholar
• Bers DM Calcium cycling and signaling in cardiac myocytes Annu Rev Physiol 2008 70 23 49 17988210
   PubMed Web of Science ®Google Scholar
• Daaka Y Luttrell LM Lefkowitz RJ Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A Nature 1997 390 6655 88 91 9363896
   PubMed Web of Science ®Google Scholar
• Movsesian MA Kukreja RC Phosphodiesterase inhibition in heart failure Handb Exp Pharmacol 2011 204 237 249 21695643
   PubMedGoogle Scholar
• Communal C Singh K Sawyer DB Colucci WS Opposing effects of beta(1)- and beta(2)-aadrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein Circulation 1999 100 22 2210 2212 10577992
   PubMed Web of Science ®Google Scholar
• Chesley A Lundberg MS Asai T The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase Circ Res 2000 87 12 1172 1179 11110775
   PubMed Web of Science ®Google Scholar
• Zhu WZ Zheng M Koch WJ Lefkowitz RJ Kobilka BK Xiao RP Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes Proc Natl Acad Sci U S A 2001 98 4 1607 1612 11171998
   PubMed Web of Science ®Google Scholar
• Dorn GW2nd Tepe NM Lorenz JN Koch WJ Liggett SB Low-and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice Proc Natl Acad Sci U S A 1999 96 11 6400 6405 10339599
   PubMed Web of Science ®Google Scholar
• Liggett SB Tepe NM Lorenz JN Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level Circulation 2000 101 14 1707 1714 10758054
   PubMed Web of Science ®Google Scholar
• Bristow MR Ginsburg R Umans V Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure Circ Res 1986 59 3 297 309 2876788
   PubMed Web of Science ®Google Scholar
• Bristow MR Ginsburg R Minobe W Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts N Engl J Med 1982 307 4 205 211 6283349
   PubMed Web of Science ®Google Scholar
• Nikolaev VO Moshkov A Lyon AR Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation Science 2010 327 5973 1653 1657 20185685
   PubMed Web of Science ®Google Scholar
• Iaccarino G Tomhave ED Lefkowitz RJ Koch WJ Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade Circulation 1998 98 17 1783 1789 9788834
   PubMed Web of Science ®Google Scholar
• Adamson PB Gilbert EM Reducing the risk of sudden death in heart failure with beta-blockers J Card Fail 2006 12 9 734 746 17174236
   PubMed Web of Science ®Google Scholar
• Birks EJ Tansley PD Hardy J Left ventricular assist device and drug therapy for the reversal of heart failure N Engl J Med 2006 355 18 1873 1884 17079761
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ Lavie CJ Fares H Menezes AR O’Keefe JH Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol) Am J Cardiol 2013 111 5 765 769 23290925
   PubMed Web of Science ®Google Scholar
• Woodcock EA Du XJ Reichelt ME Graham RM Cardiac alpha 1-adrenergic drive in pathological remodelling Cardiovasc Res 2008 77 3 452 462 18032391
   PubMed Web of Science ®Google Scholar
• Shannon R Chaudhry M Effect of alpha1-adrenergic receptors in cardiac pathophysiology Am Heart J 2006 152 5 842 850 17070143
   PubMed Web of Science ®Google Scholar
• Knowlton KU Michel MC Itani M The alpha 1 A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy J Biol Chem 1993 268 21 15374 15380 8393439
   PubMed Web of Science ®Google Scholar
• Du XJ Gao XM Kiriazis H Transgenic alpha1 A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival Cardiovasc Res 2006 71 4 735 743 16859660
   PubMed Web of Science ®Google Scholar
• Huang Y Wright CD Merkwan CL An alpha1A-adrenergic extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes Circulation 2007 115 6 763 772 17283256
   PubMed Web of Science ®Google Scholar
• Esposito G Prasad SV Rapacciuolo A Mao L Koch WJ Rockman HA Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload Circulation 2001 103 10 1453 1458 11245652
   PubMed Web of Science ®Google Scholar
• Hwang H Robinson DA Stevenson TK PKCβII modulation of myocyte contractile performance J Mol Cell Cardiol 2012 53 2 176 186 22587992
   PubMed Web of Science ®Google Scholar
• Philipp M Hein L Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes Pharmacol Ther 2004 101 1 65 74 14729393
   PubMed Web of Science ®Google Scholar
• Philipp M Brede M Hein L Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough Am J Physiol Regul Integr Comp Physiol 2002 283 2 R287 R295 12121839
   PubMed Web of Science ®Google Scholar
• Hein L Altman JD Kobilka BK Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission Nature 1999 402 6758 181 184 10647009
   PubMed Web of Science ®Google Scholar
• Brede M Wiesmann F Jahns R Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure Circulation 2002 106 19 2491 2496 12417548
   PubMed Web of Science ®Google Scholar
• Brede M Nagy G Philipp M Sorensen JB Lohse MJ Hein L Differential control of adrenal and sympathetic catecholamine release by alpha2-adrenoceptor subtypes Mol Endocrinol 2003 17 8 1640 1646 12764077
   PubMedGoogle Scholar
• Lymperopoulos A Rengo G Koch WJ Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation Trends Mol Med 2007 13 12 503 511 17981507
   PubMed Web of Science ®Google Scholar
• Small KM Wagoner LE Levin AM Kardia SL Liggett SB Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure N Engl J Med 2002 347 15 1135 1142 12374873
   PubMed Web of Science ®Google Scholar
• Neumeister A Charney DS Belfer I Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoceptor gene polymorphism in healthy humans Pharmacogenet Genomics 2005 15 3 143 149 15861038
   PubMed Web of Science ®Google Scholar
• Cohn JN Levine TB Olivari MT Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 1984 311 13 819 823 6382011
   PubMed Web of Science ®Google Scholar
• Floras JS The “unsympathetic” nervous system of heart failure Circulation 2002 105 15 1753 1755 11956112
   PubMed Web of Science ®Google Scholar
• Rengo G Lymperopoulos A Zincarelli C Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure Circulation 2009 119 1 89 98 19103992
   PubMed Web of Science ®Google Scholar
• Port JD Bristow MR Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure J Mol Cell Cardiol 2001 33 5 887 905 11343413
   PubMed Web of Science ®Google Scholar
• Bristow MR Beta-adrenergic receptor blockade in chronic heart failure Circulation 2000 101 5 558 569 10662755
   PubMed Web of Science ®Google Scholar
• Cohn JN Pfeffer MA Rouleau J MOXCON Investigators Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) Eur J Heart Fail 2003 5 5 659 667 14607206
   PubMed Web of Science ®Google Scholar
• Kao DP Wagner BD Robertson AD Bristow MR Lowes BD A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol PLoS One 2012 7 11 e48184 23144856
   PubMed Web of Science ®Google Scholar
• Aggarwal A Esler MD Socratous F Kaye DM Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure J Am Coll Cardiol 2001 37 5 1246 1251 11300430
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group N Engl J Med 1987 316 23 1429 1435 2883575
   PubMed Web of Science ®Google Scholar
• Cohn JN Johnson G Ziesche S A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 1991 325 5 303 310 2057035
   PubMed Web of Science ®Google Scholar
• Francis GS Benedict C Johnstone DE Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 1990 82 5 1724 1729 2146040
   PubMed Web of Science ®Google Scholar
• Weber K Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation Circuation 1997 96 11 4065 4082
   Web of Science ®Google Scholar
• Schieffer B Wirger A Meybrunn M Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat Circulation 1994 89 5 2273 2282 8181153
   PubMed Web of Science ®Google Scholar
• Lang CC Struthers AD Targeting the renin-angiotensin-aldosterone system in heart failure Nat Rev Cardiol 2013 10 3 125 134 23319100
   PubMed Web of Science ®Google Scholar
• Kaoukis A Deftereos S Raisakis K The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition Curr Top Med Chem 2013 13 2 95 114 23470073
   PubMed Web of Science ®Google Scholar
• Kaluski E Kobrin I Zimlichman R RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study J Am Coll Cardiol 2003 41 2 204 210 12535809
   PubMed Web of Science ®Google Scholar
• Mustafa SJ Morrison RR Teng B Pelleg A Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology Handb Exp Pharmacol 2009 193 161 188 19639282
   PubMedGoogle Scholar
• Nell PG Albrecht-Küpper B The adenosine A1 receptor and its ligands Prog Med Chem 2009 47 163 201 19328291
   PubMedGoogle Scholar
• Sabbah HN Gupta RC Kohli S Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure Circ Heart Fail 2013 6 3 563 571 23564604
   PubMed Web of Science ®Google Scholar
• Nishikimi T Kuwahara K Nakagawa Y Kangawa K Nakao K Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application Curr Protein Pept Sci 2013 14 4 256 267 23745694
   PubMed Web of Science ®Google Scholar
• Hong Y Hay DL Quirion R Poyner DR The pharmacology of adrenomedullin 2/intermedin Br J Pharmacol 2012 166 1 110 120 21658025
   PubMed Web of Science ®Google Scholar
• Yoshizawa T Sakurai T Kamiyoshi A Novel regulation of cardiac metabolism and homeostasis by the adrenomedullin-receptor activity-modifying protein 2 system Hypertension 2013 61 2 341 351 23297372
   PubMed Web of Science ®Google Scholar
• Bathgate RA Halls ML van der Westhuizen ET Callander GE Kocan M Summers RJ Relaxin family peptides and their receptors Physiol Rev 2013 93 1 405 480 23303914
   PubMed Web of Science ®Google Scholar
• Metra M Cotter G Davison BA Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes J Am Coll Cardiol 2013 61 2 196 206 23273292
   PubMed Web of Science ®Google Scholar
• Wang J Li S Corticotropin-releasing factor family and its receptors: tumor therapeutic targets? Biochem Biophys Res Commun 2007 362 4 785 788 17822675
   PubMed Web of Science ®Google Scholar
• Emeto TI Moxon JV Rush C Woodward L Golledge J Relevance of urocortins to cardiovascular disease J Mol Cell Cardiol 2011 51 3 299 307 21689660
   PubMed Web of Science ®Google Scholar
• Davis ME Pemberton CJ Yandle TG Urocortin 2 infusion in human heart failure Eur Heart J 2007 28 21 2589 2597 17720993
   PubMed Web of Science ®Google Scholar
• Gheorghiade M Greene SJ Ponikowski P Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction Eur J Heart Fail 2013 15 6 679 689 23471413
   PubMed Web of Science ®Google Scholar
• Holmes CL Landry DW Granton JT Science review: Vasopressin and the cardiovascular system part 1. Receptor physiology Crit Care 2003 7 6 427 434 14624682
   PubMed Web of Science ®Google Scholar
• Gassanov N Semmo N Semmo M Nia AM Fuhr U Er F Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH) Eur J Clin Pharmacol 2011 67 4 333 346 21327910
   PubMed Web of Science ®Google Scholar
• Ambrosy AP Vaduganathan M Mentz RJ Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial Am Heart J 2013 165 2 216 225 23351825
   PubMed Web of Science ®Google Scholar
• Kinugawa K Imamura T Komuro I Experience of a vasopressin receptor antagonist, tolvaptan under the unique indication in Japanese heart failure patients Clin Pharmacol Ther Epub July 19 2013
   Web of Science ®Google Scholar
• Ussher JR Drucker DJ Cardiovascular biology of the incretin system Endocr Rev 2012 33 2 187 215 22323472
   PubMed Web of Science ®Google Scholar
• Lorber D GLP-1 receptor agonists: effects on cardiovascular risk reduction Cardiovasc Ther 2013 31 4 238 249 23865382
   PubMed Web of Science ®Google Scholar
• Brubaker PL Minireview: update on incretin biology: focus on glucagon-like peptide-1 Endocrinology 2010 151 5 1984 1989 20305008
   PubMed Web of Science ®Google Scholar
• Surma M Wei L Shi J Rho kinase as a therapeutic target in cardiovascular disease Future Cardiol 2011 7 5 657 671 21929346
   PubMedGoogle Scholar
• Hattori T Shimokawa H Higashi M Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice Circulation 2004 109 18 2234 2239 15096457
   PubMed Web of Science ®Google Scholar
• McKinsey TA Kass DA Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface Nat Rev Drug Discov 2007 6 8 617 635 17643091
   PubMed Web of Science ®Google Scholar
• Schmidt M Dekker FJ Maarsingh H Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions Pharmacol Rev 2013 65 2 670 709 23447132
   PubMed Web of Science ®Google Scholar
• Pereira L Cheng H Lao DH Epac2 mediates cardiac β1-adrenergic-dependent sarcoplasmic reticulum Ca2+ leak and arrhythmia Circulation 2013 127 8 913 922 23363625
   PubMed Web of Science ®Google Scholar
• Reiter E Lefkowitz RJ GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling Trends Endocrinol Metab 2006 17 4 159 165 16595179
   PubMed Web of Science ®Google Scholar
• Ferguson SS Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling Pharmacol Rev 2001 53 1 1 24 11171937
   PubMed Web of Science ®Google Scholar
• Arriza JL Dawson TM Simerly RB The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain J Neurosci 1992 12 10 4045 4055 1403099
   PubMed Web of Science ®Google Scholar
• Rockman HA Koch WJ Lefkowitz RJ Seven-transmembrane-spanning receptors and heart function Nature 2002 415 6868 206 212 11805844
   PubMed Web of Science ®Google Scholar
• Belmonte SL Blaxall BC G protein coupled receptor kinases as therapeutic targets in cardiovascular disease Circ Res 2011 109 3 309 319 21778435
   PubMed Web of Science ®Google Scholar
• Rengo G Lymperopoulos A Leosco D Koch WJ GRK2 as a novel gene therapy target in heart failure J Mol Cell Cardiol 2011 50 5 785 792 20800067
   PubMed Web of Science ®Google Scholar
• Ungerer M Böhm M Elce JS Erdmann E Lohse MJ Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart Circulation 1993 87 2 454 463 8381058
   PubMed Web of Science ®Google Scholar
• Koch WJ Rockman HA Samama P Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor Science 1995 268 5215 1350 1353 7761854
   PubMed Web of Science ®Google Scholar
• Thal DM Homan KT Chen J Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility ACS Chem Biol 2012 7 11 1830 1839 22882301
   PubMed Web of Science ®Google Scholar
• Eschenhagen T Beta-adrenergic signaling in heart failure: adapt or die Nat Med 2008 14 5 485 487 18463653
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Rengo G Funakoshi H Eckhart AD Koch WJ Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure Nat Med 2007 13 3 315 323 17322894
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Bathgate A Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown Pharmacogenomics 2012 13 3 323 341 22304582
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Rengo G Gao E Ebert SN Dorn GW2nd Koch WJ Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction J Biol Chem 2010 285 21 16378 16386 20351116
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Beta-arrestin biased agonism/antagonism at cardiovascular seven transmembrane-spanning receptors Curr Pharm Des 2012 18 2 192 198 22229558
   PubMed Web of Science ®Google Scholar
• Noor N Patel CB Rockman HA B-arrestin: a signaling molecule and potential therapeutic target for heart failure J Mol Cell Cardiol 2011 51 4 534 541 21074538
   PubMed Web of Science ®Google Scholar
• Tilley DG G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function Circ Res 2011 109 2 217 230 21737817
   PubMed Web of Science ®Google Scholar
• Zhai P Yamamoto M Galeotti J Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice J Clin Invest 2005 115 11 3045 3056 16276415
   PubMed Web of Science ®Google Scholar
• Rajagopal K Whalen EJ Violin JD Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes Proc Natl Acad Sci U S A 2006 103 44 16284 16289 17060617
   PubMed Web of Science ®Google Scholar
• Aplin M Christensen GL Schneider M Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes Basic Clin Pharmacol Toxicol 2007 100 5 296 301 17448114
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Rengo G Zincarelli C Kim J Soltys S Koch WJ An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo Proc Natl Acad Sci U S A 2009 106 14 5825 5830 19289825
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A Rengo G Zincarelli C Kim J Koch WJ Adrenal Beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels J Am Coll Cardiol 2011 57 3 356 365 21232674
   PubMed Web of Science ®Google Scholar